Transcend Therapeutics
Sarah completed her PhD in Behavioral Neuroscience at the University of South Carolina under an interdisciplinary T32 grant. She was also a post-doctoral T32 awardee at the Johns Hopkins University, where she demonstrated that sleep fragmentation results in neuroinflammation independent of disease. After her postdoctoral work, she worked as a Principal Scientist at Longevity Biotech where she investigated the contribution of the adaptive immune system on neurodegenerative diseases and the efficacy of a novel peptide drug. Her career has focused on the effects of neuroinflammation on development and its contribution to neurological disease. Both her technical and analytical expertise, in addition to her grantsmanship, have contributed to more than $10 million in grant funding over the course of her career.
This person is not in any teams
This person is not in any offices
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.